Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($1.0 million vs $138,068), about 7.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | MDCX |
|---|---|---|
| Share price | $0.4602 | $0.0921 |
| Market cap | $1.01M | $138.07K |
| 1-day change | -12.13% | -9.62% |
| YTD return | — | -93.98% |
| 1-year return | — | -96.33% |
| P/E ratio (TTM) | 0.01 | — |
| EPS (TTM) | $63.74 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $139.00 |
| 52-week low | $0.45 | $0.084 |
| Distance from 52-week high | -99.12% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +1836.11% | +4785.99% |
| Average volume | 3.72M | 92.96K |
| Shares outstanding | 2.20M | 1.50M |
| Employees | 11 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biodexa Pharmaceuticals American Depositary Shs is about 7.3 times larger than Medicus Pharma by market value ($1.01M vs $138.07K).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
BDRX vs MDCX FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Medicus Pharma?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $1.01M compared with $138.07K for Medicus Pharma (MDCX).
Are Biodexa Pharmaceuticals American Depositary Shs and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.